| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8821927 | NOVARTIS | Pharmaceutical composition |
Sep, 2029
(5 years from now) | |
Tykerb is owned by Novartis.
Tykerb contains Lapatinib Ditosylate.
Tykerb has a total of 1 drug patent out of which 0 drug patents have expired.
Tykerb was authorised for market use on 13 March, 2007.
Tykerb is available in tablet;oral dosage forms.
The generics of Tykerb are possible to be released after 18 September, 2029.
Drugs and Companies using LAPATINIB DITOSYLATE ingredient
Market Authorisation Date: 13 March, 2007
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of TYKERB before it's drug patent expiration?
More Information on Dosage
TYKERB family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic